Trial Profile
A Phase II, Multi-center, Randomized and Open Study to Evaluate and Compare the PK, PD and Safety of SCT400 With Rituximab in Patients With CD20+ B-cell Non-Hodgkin's Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ripertamab (Primary) ; Rituximab
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors Sinocelltech
- 03 Jun 2015 New trial record